论文部分内容阅读
目的:探讨非小细胞肺癌胸水细胞块在ROS1(c-ros oncogene 1,receptor tyrosine kinase)融合基因突变检测中的临床价值。方法:采用ARMS-PCR法检测215例非小细胞肺癌胸水细胞块和404例非小细胞肺癌组织块中ROS1基因融合的四种类型,并检测细胞块同时送检组织块的患者74例的一致性。结果:细胞块ROS1融合基因阳性7例,阳性率3.26%(7/215);组织块ROS1融合基因阳性8例,阳性率1.98%(8/404);74例有组织块对照的细胞块ROS1融合基因结果一致性有71例,一致率达9 5.9 5%(7 1/7 4),其中细胞块RO S 1融合基因的阳性率2.7 0%(2/7 4),组织块阳性率6.7 6%(5/7 4)。结论:非小细胞肺癌胸水细胞块ROS1融合基因的阳性率略高于组织块;有恶性胸水的非小细胞肺癌患者原发灶组织发生ROS1融合基因阳性的概率较高。
Objective: To investigate the clinical value of the pleural effusion cell block of non-small cell lung cancer in the detection of the mutation of c-ros oncogene 1 (receptor tyrosine kinase) fusion gene. METHODS: Four types of ROS1 gene fusion in 215 non-small cell lung cancer cell masses and 404 non-small cell lung cancer cell masses were detected by ARMS-PCR and the same was detected in 74 patients Sex. Results: The positive rate of ROS1 fusion gene in cell mass was 7 (3.26%, 7/215). The positive rate of ROS1 fusion gene in tissue mass was 8% (8/404). The positive rate of ROS1 The coincidence rate of fusion gene was 71.9% (7 1/7 4). The positive rate of RO S 1 fusion gene was 2.7 0% (2/7 4) and the positive rate of tissue mass was 6.7 6% (5/7 4). Conclusion: The positive rate of ROS1 fusion gene in pleural effusion cells of non-small cell lung cancer is slightly higher than that of tissue mass. The probability of positive ROS1 fusion gene is higher in patients with malignant hydrothorax and non-small cell lung cancer.